BioCentury
ARTICLE | Finance

Bacterial brain

Why Sequoia is backing Cortexyme’s Alzheimer’s hypothesis by leading $76M round

June 1, 2018 10:05 PM UTC

Preclinical data backing Cortexyme Inc.’s hypothesis that a bacterial pathogen drives Alzheimer’s disease, combined with clinical safety data, convinced Sequoia Capital to lead the company’s $76 million series B.

The round closed on May 31 with participation from fellow new investors Vulcan Capital, Verily Life Sciences LLC, EPIQ Capital Group, RSL Investments, Huizenga Capital and an undisclosed long-term mutual fund as well as existing investors Pfizer Inc. (NYSE:PFE), Takeda Ventures, Lamond Family, Breakout Ventures and Dolby Family Ventures...

BCIQ Company Profiles

Sequoia Capital